November 25, 2019 | Big Pharma selects Kneat’s SaaS Platform for Digitalization of its Validation Work Processes

Investor News : 25 Nov 2019

LIMERICK, Ireland November 25, 2019/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce that it has signed a five-year master service agreement with another one of the worlds largest pharmaceutical companies, to digitalize key validation processes across its manufacturing sites. Implementation has begun with an expected phase one Go Live on the lead site in Q1 2020. This agreement allows the customer and its affiliates, with more than 60,000 employees worldwide, to expand Kneat across all its global sites, representing a significant opportunity for growth and expansion of Kneat’s platform.

“We are excited to be the chosen solution by this global leader and we look forward to working closely with their global teams to digitalize all aspects of their validation processes”, said Eddie Ryan, Chief Executive Officer of Kneat. “This company is a standard setter within Life Sciences and we are very proud to add them to our growing customer list of tier one global healthcare companies.”

 

About Kneat

Kneat, a Canadian company with operational headquarters in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform (“Kneat Gx”). Multiple business processes can be configured on Kneat Gx from equipment to computer system validation, through to quality document management. Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world-wide. Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard. For more information visit www.kneat.com.


Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and the customer, Kneat’s business development activities, the use and implementation timelines of Kneat’s software within the customer’s validation processes, the ability and intent of the customer to scale the use of Kneat’s software within the customer’s organization and the compliance of Kneat’s platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors’ own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Hugh Kavanagh, Chief Financial Officer, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: investors@kneat.com

Sign up to Investor News

Contact

Talk to us

Find out how Kneat can make your validation easier, faster, and smarter.
Start your paperless validation revolution by speaking to our experts.

Europe: +353-61-203826
USA: (813)-503-6654
Canada: 1-902-442-7185